Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care. To learn more…
Boehringer Ingelheim and Palatin Technologies enter into a global research collaboration and licensing agreement
(Image Credit: AdobeStock/Vittaya_25) Boehringer Ingelheim and Palatin Technologies have entered into a global research collaboration and licensing agreement to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases. Under the terms of the agreement, Palatin will receive…
Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye – Nature
Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye Nature Source: Author: | Date: 2025-07-04 07:00:00 Source: Author: | Date: 2025-07-04 07:00:00
New research uncovers promising treatment for neurodegenerative diseases like ALS, glaucoma | Ophthalmology – Stanford Medicine
New research uncovers promising treatment for neurodegenerative diseases like ALS, glaucoma | Ophthalmology Stanford Medicine Source: Author: | Date: 2025-02-20 08:00:00 Source: Author: | Date: 2025-02-20 08:00:00
Glaukos Submits FDA Application for Epioxa Therapy
Glaukos Corporation has officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its innovative corneal cross-linking therapy, Epioxa (Epi-on). This next-generation treatment is designed for patients with keratoconus and represents a significant advancement…
4DMT Reveals Preclinical Data on TVE Platform
4D Molecular Therapeutics (4DMT) has announced the publication of preclinical data underscoring the capabilities of its Therapeutic Vector Evolution (TVE) platform. The research focuses on the intravitreal R100 vector and the R100-based genetic medicine 4D-150. This groundbreaking study, titled “Design…
Sepul Bio Launches Ultevursen Phase 2b Trial for RP
Sepul Bio has announced the dosing of the first patient in the LUNA clinical study, a Phase 2b trial evaluating ultevursen for the treatment of USH2A-associated retinitis pigmentosa (RP). This milestone represents renewed hope for individuals affected by this debilitating…
Opus Gets FDA SPA for APX3330 Phase 3 Trial
Opus Genetics has announced a key regulatory milestone, securing a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial of APX3330. The oral treatment is being evaluated for moderate to…
EYLEA HD Succeeds in Phase 3 RVO Trial
Regeneron Pharmaceuticals has announced that its Phase 3 QUASAR trial evaluating EYLEA HD (aflibercept 8 mg) has met its primary endpoint, marking a significant advancement in the treatment of retinal vein occlusion (RVO). About the QUASAR Trial The QUASAR trial…
Aurion’s AURN001 Shows Positive Phase 1/2 Results
Aurion Biotech has released topline data from its Phase 1/2 clinical trial (CLARA), evaluating AURN001, an allogeneic cell therapy product candidate for treating corneal edema secondary to corneal endothelial dysfunction. These results highlight the therapy’s potential as a groundbreaking treatment…